Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions noted, no amendment — page 5

The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.

Submissions

127 documents · page 5 of 5

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-PANCREATITIS/009Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Adaeze Dunmore-EkpoA superseded version should remain reachable from the version that replaced it
DRAFT-PRIMARY-VS-S/003Draft synthesis: Cardiovascular benefit in primary compared with…Dr Georgiana MountstephenDeclared interests should appear on the document rather than on a separate page
DRAFT-TIRZEPATIDE-/007Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Ottoline Oppenheimer-AdeA sortable table implies a comparison the underlying data do not support
DRAFT-TIRZEPATIDE-/001Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Quentin Whitmarsh-ObiA superseded version should remain reachable from the version that replaced it
DRAFT-PEPTIDE-PURI/003Draft synthesis: Dependence of reported purity on the analytical…Dr Katarzyna Oppenheimer-AdeA sortable table implies a comparison the underlying data do not support
DRAFT-MITOCHONDRIA/007Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Wilhelmina WintringhamA superseded version should remain reachable from the version that replaced it
DRAFT-MITOCHONDRIA/004Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Eamon ImmelmannDeclared interests should appear on the document rather than on a separate page

page 5 of 5

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.